BTK and B-cell chronic lymphocytic leukemia: In the first study reporting CLL relapse on acalabrutinib, resistance was shown to be mediated predominantly by BTK mutations with 69% of cases carrying a C481S/R/Y mutation and one out of sixteen having both C481S and T474I mutations.